A neurogenetic model for the study of schizophrenia spectrum disorders: the International 22q11.2 Deletion Syndrome Brain Behavior Consortium
- PMID: 28761081
- PMCID: PMC5935262
- DOI: 10.1038/mp.2017.161
A neurogenetic model for the study of schizophrenia spectrum disorders: the International 22q11.2 Deletion Syndrome Brain Behavior Consortium
Abstract
Rare copy number variants contribute significantly to the risk for schizophrenia, with the 22q11.2 locus consistently implicated. Individuals with the 22q11.2 deletion syndrome (22q11DS) have an estimated 25-fold increased risk for schizophrenia spectrum disorders, compared to individuals in the general population. The International 22q11DS Brain Behavior Consortium is examining this highly informative neurogenetic syndrome phenotypically and genomically. Here we detail the procedures of the effort to characterize the neuropsychiatric and neurobehavioral phenotypes associated with 22q11DS, focusing on schizophrenia and subthreshold expression of psychosis. The genomic approach includes a combination of whole-genome sequencing and genome-wide microarray technologies, allowing the investigation of all possible DNA variation and gene pathways influencing the schizophrenia-relevant phenotypic expression. A phenotypically rich data set provides a psychiatrically well-characterized sample of unprecedented size (n=1616) that informs the neurobehavioral developmental course of 22q11DS. This combined set of phenotypic and genomic data will enable hypothesis testing to elucidate the mechanisms underlying the pathogenesis of schizophrenia spectrum disorders.
Conflict of interest statement
DMM-M has given lectures on 22q11DS for Natera; CA has been a consultant to or has received honoraria or grants from Abbot, AMGEN, AstraZeneca, CIBERSAM, Dainippon Sumitomo Pharma, Fundación Alicia Koplowitz, Forum, Instituto de Salud Carlos III, Gedeon Richter, Janssen Cilag, Lundbeck, Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía y Competitividad, Mutua Madrileña, Otsuka, Pfizer, Roche, Servier, Shire, Schering Plough, Sunovio and Takeda. DF has been a consultant and/or advisor to or has received honoraria from AstraZeneca, Bristol-Myers Squibb, Eisai, Janssen, Lundbeck, Otsuka and Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía. The other authors declare no conflict of interest.
Figures


References
-
- Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008;320:539–543. - PubMed
-
- Shprintzen RJ, Goldberg R, Golding-Kushner KJ, Marion RW. Late-onset psychosis in the velo-cardio-facial syndrome. Am J Med Genet. 1992;42:141–142. - PubMed
MeSH terms
Grants and funding
- U01 MH087626/MH/NIMH NIH HHS/United States
- U01 MH101719/MH/NIMH NIH HHS/United States
- R01 MH085953/MH/NIMH NIH HHS/United States
- U54 HD079125/HD/NICHD NIH HHS/United States
- R01 MH064824/MH/NIMH NIH HHS/United States
- UL1 TR000454/TR/NCATS NIH HHS/United States
- L30 MH111007/MH/NIMH NIH HHS/United States
- UL1 TR002378/TR/NCATS NIH HHS/United States
- U01 MH101724/MH/NIMH NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- U01 MH101722/MH/NIMH NIH HHS/United States
- U01 MH101720/MH/NIMH NIH HHS/United States
- U01 MH101723/MH/NIMH NIH HHS/United States
- MR/L010305/1/MRC_/Medical Research Council/United Kingdom
- G0800509/MRC_/Medical Research Council/United Kingdom
- R37 MH085953/MH/NIMH NIH HHS/United States
- U01 MH087636/MH/NIMH NIH HHS/United States
- P01 HD070454/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources